%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Bado, G.
%A Penot, P.
%A N'Diaye, M. D.
%A Amiel, C.
%A Hema, A.
%A Kamboule, E. B.
%A Guiard-Schmid, J. B.
%A Kabore, N. F.
%A Slama, L.
%A Bambara, A.
%A Laurent, Christian
%A Sangare, L.
%A Sawadogo, A. B.
%T Hepatitis B seroprevalence in HIV-infected patients consulting in a public day care unit in Bobo Dioulasso, Burkina Faso
%D 2013
%L fdi:010060509
%G ENG
%J Medecine et Maladies Infectieuses
%@ 0399-077X
%K HIV/HBV co-infection ; Hepatitis B ; HBV surface antigen
%K BURKINA FASO
%M ISI:000322099900005
%N 5
%P 202-207
%R 10.1016/j.medmal.2013.04.001
%U https://www.documentation.ird.fr/hor/fdi:010060509
%> https://www.documentation.ird.fr/intranet/publi/2013/08/010060509.pdf
%V 43
%W Horizon (IRD)
%X Objective. - The authors had for aim to assess the prevalence of hepatitis B co-infection in a cohort of HIV-infected patients, routinely followed-up at the Day Care Unit of the Bobo Dioulasso Sanou Souro University Hospital, Burkina Faso. Patients and methods. - The Elisa technique was used to dose HBs antigen (AgHBs), antibodies anti-HBs and anti-HBc in all the patients followed by the biological laboratory, from October to December 2008. Results. - The AgHBs prevalence was 12.7% [CI at 95%; 10.7-15.0%] and men were slightly more likely to be positive for AgHBs than women (16.5% [12.0-21.9%] versus 11.6% [9.4-14.1%]; P = 0.047); 83.3% of the patients [80.8-85.6%] were positive for hepatitis B core antibody, and 32.6% [29.7-35.6%] for hepatitis B surface antibody; 29.9% of the patients [27.1-32.8%] had a complete profile of former hepatitis B infection, 41.3% [38.2-44.4%] expressed core antibodies only; 13.8% [11.7-16.0%] had a negative serological test, and 2.3% [1.5-3.4%] presented a vaccinal immunity. Conclusion. - These results stress the usefulness of screening for hepatitis B in all HIV-infected patients, along with the initial biological tests. This would help adapt HIV treatment to co-infected patients and to build an expanded program of vaccination for non-immune patients.
%$ 052